Newer antibiotics for the treatment of respiratory tract infections

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 3, 2004, Pages 189-196

  Blasi, Francesco ^a   Tarsia, Paolo ^a   Cosentini, Roberto ^b   Valenti, Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Antimicrobial resistance; Cationic peptides; Fluoroquinolones; Glycopeptides; Glycylcyclines; Ketolides; Lipopeptides; Lower respiratory tract infections; Novel compounds; Oxazolidinones; Streptogramins; lactams

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LINEZOLID; LIPOPEPTIDE; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR; OXAZOLIDINONE DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; POSIZOLID; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; RIFAMYCIN DERIVATIVE; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TRINEM DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HEALTH CARE PERSONNEL; HUMAN; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 1942468740     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200405000-00008     Document Type: Review

References (52)

1. Shortridge VD, Zhong P, Cao Z, et al.: Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002, 46:783-786.
2. Kim MK, Zhou W, Tessier PR, et al.: Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 2002, 46:3185-3192.
3. Pai SR, Singh KV, Murray BE: In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model. Antimicrob Agents Chemother 2003, 47:2706-2709.
4. Hammerschlag MR, Reznik T, Roblin PM, et al.: Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumoniae due to Chlamydia pneumonias. J Antimcrob Chemother 2003, 51:1025-1028.
5. Miyashita N, Fukano H, Yoshida K, et al.: In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2003, 52:497-499.
6. Jung R, Danziger LH, Pendland SL: Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila. J Antimicrob Chemother 2002, 49:857-861.
7. Swaney SM, Aoki H, Ganoza MC, et al.: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998, 42:3251-3255.
8. Mutnick AH, Biedenbach DJ, Turnidge JD, et al.: Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002, 43:65-73.
9. Conte JE Jr, Golden JA, Kipps J, et al.: Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002, 46:1475-1480.
10. San Pedro GS, Cammarata SK, Oliphant TH, et al.: Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002, 34:720-728.
11. Stevens DL, Herr D, Lampiris H, et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
12. Saiman L, Goldfarb J, Kaplan SA, et al.: Pediatr Infect Dis J 2003, 22(suppl 9): S193-S200.
13. Linden P: Use of linezolid for gram-positive infections. Infect Med 2002, 19:25-32.
14. Attassi K, Hershberger E, Alam R, et al.: Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002, 34:695-698.
15. Li JZ, Willke RJ, Rittenhouse BE, et al.: Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 2002, 22:45S-54S.
16. Hoellman DB, Lin G, Ednie LM, et al.: Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother 2003, 47:1148-1150.
17. Fluit AC, Schmitz FJ, Verhoef J, et al.: In vitro activity of AZD2563, a novel oxazolidinone, against European gram-positive cocci. J Antimicrob Chemother 2002, 50:271-276.
18. Yong D, Yum JH, Lee K, et al.: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2004, 48:352-357.
19. Klastersky J: Role of quinupristin/dalfopristin in the treatment of gram-positive nosocomial infections in haematological or oncological patients. Cancer Treat Rev 2003, 29:431-440.
20. De Gaudio AR, Di Filippo A: What is the role of streptogramins in intensive care? J Chemother 2003, 15(suppl 3):17-21.
21. Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections. Curr Opin Pharmacol 2003, 3:464-469.
22. Schwenger V, Mundlein E, Dagrosa EE, et al.: Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report. Infection 2002, 30:257-261.
23. Weinberg JM: Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin. J Drugs Dermatol 2003, 2:378-83.
24. Carver PL, Whang E, VandenBussche HL, et al.: Risk factors for arthralgias or myalgias associated with quinupristin/dalfopristin. Pharmacotherapy 2003, 23:159-164.
25. Pankuch GA, Kelly LM, Lin G, et al.: Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species. Antimicrob Agents Chemother 2003, 47:3270-3274.
26. Low DE, Kreiswirth BN, Weiss K, et al.: Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents 2002, 20:220-222.
27. Milatovic D, Schmitz FJ, Verhoef J, et al.: Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003, 47:400-404.
28. Chopra I: New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002, 5:119-125. This is an interesting review on glycylcyclines and new inhibitors of efflux pumps. The author considers the current status of glycyclines and the possibility that resistance to these agents might arise in the future
29. Ueda Y, Sunagawa M: In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1 beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antiomicrob Agents Chemother 2003, 476:2471-2430.
30. Allen NE, Nicas TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003, 26:511-532.
31. Gerber J, Smirnov A, Welmer A, et al.: Activity of LY333328 in experimental meninigitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001, 42:2452-2455.
32. Seltzer E, Dorr MB, Goldstein BP, et al.: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
33. Goldstein EJ, Citron DM, Merriam CV, et al.: In vitro activities of dalbavancin and nine comprator agents against anaerobic gram-positive species and corynebacyteria. Antimicrob Agents Chemother 2003, 47:1968-1971.
34. McCafferty DG, Cudic P, Frankel BA, et al.: Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 2002, 66:261-284.
35. Cudic P, Behenna DC, Kranza JK, et al.: Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin. Chem Biol 2002, 9:897-906. An interesting analysis of the mechanism of action of the new inhibitor of peptiglycan biosynthesis ramoplanin
36. Kauffman CA: Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003, 51(suppl 3):23-30.
37. Brogden KA, Ackermann M, McCray PB Jr, et al.: Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents 2003, 22:465-478.
38. Stark M, Liu LP, Deber CM: Cationic hydrophobic peptides with antimicrobial activity. Antimicrob Agents Chemother 2002, 46:3585-3590.
39. Cirioni O, Giacometti A, Ghiselli R, et al.: Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. Antimicrob Agents Chemother 2002, 46:101-104.
40. Navon-Venezia S, Feder R, Gaidukov L, et al.: Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother 2002, 46:689-694.
41. Clayberger C, Krensky AM: Granulysin. Curr Opin Immunol 2003, 15:560-565. An overview on Granulysin, a molecule expressed by human natural killer cells and activated T lymphocytes, exhibits cytolytic activity against a variety of microbes
42. Hamamoto K, Kida Y, Zhang Y, et al.: Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002, 46:741-749.
43. Toney JH: Iseganan (IntraBiotics pharmaceuticals). Curr Opin Investig Drugs 2002, 3:225-228.
44. Wise R, Andrews JM, Ashby J: In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob Agents Chemother 2002, 46:1117-1118.
45. Bowker KE, Noel AR, MacGowan AP: In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int J Antimicrob Agents 2003, 22:557-561.
46. Jones RN, Rhomberg PR: Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother 2003, 51:157-161.
47. Roblin PM, Hammerschlag MR: In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob Agents Chemother 2003, 47:1447-1448.
48. Azoulay-Dupuis E, Mohler J, Bedos JP: Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 2004, 48:80-85.
49. Hackbarth CJ, Chen DZ, Lewis JG, et al.: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002, 46:2752-2764.
50. East SP, Beckett RP, Brookings DC, et al.: Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg Med Chem Lett 2004, 14:59-62.
51. Weidenmaier C, Kristian SA, Peschel A: Bacterial resistance to antimicrobial host defenses-an emerging target for novel antiinfective strategies? Curr Drug Targets 2003, 4:643-649.
52. Cazzola M, Matera MG, Page CP: Novel approaches to the treatment of pneumonia. Trends Pharmacol Sci 2003, 24:306-314. This is an outstanding review of the possible new approaches to the treatment of pneumonia. The authors analyze the inhibitors of new bacterial targets, including inhibitors of genes that are required for either virulence or pathogenesis.